Eliquis

Eliquis, the brand name for apixaban, is an anticoagulant medication co-developed by Bristol-Myers Squibb and Pfizer. Approved by the FDA in 2012, Eliquis is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban works by directly inhibiting factor Xa, an essential component in the blood clotting process, which helps prevent the formation of harmful blood clots. Eliquis is typically taken as an oral tablet twice daily. Patients should adhere to their prescribed regimen and maintain regular consultations with their healthcare provider to monitor for any potential side effects or interactions with other medications.